API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-says-ms-drug-fails-late-stage-trials-2023-12-05/
https://www.fiercebiotech.com/biotech/merck-kgaa-hold-still-clouding-prospects-guides-ms-drug-past-durability-test-ahead-phase-3
https://endpts.com/merck-kgaas-btk-inhibitor-hit-by-partial-clinical-hold-over-safety-concern-but-phiii-readout-unaffected/
https://www.fiercebiotech.com/biotech/merck-kgaa-phase-3-data-horizon-showcases-durability-evobrutinib-multiple-sclerosis
https://health.economictimes.indiatimes.com/news/industry/india-will-have-to-play-key-role-in-mass-production-of-coronavirus-vaccine-france/75951934
https://endpts.com/merck-kgaa-touts-fda-breakthrough-status-blockbuster-potential-in-bid-to-investors/
https://www.prnewswire.com/news-releases/positive-phase-ii-data-further-highlights-clinical-proof-of-concept-for-evobrutinib-first-oral-brutons-tyrosine-kinase-btk-inhibitor-to-report-positive-phase-ii-clinical-results-in-ms-300848230.html
https://www.reuters.com/article/us-esmo-merckkgaa-alliance/merck-kgaa-says-might-strike-partnership-deal-this-year-idUSKCN1MV0VN
https://endpts.com/merck-kgaa-posts-mixed-data-from-their-big-phiib-ms-study-on-evobrutinib-spurring-plenty-of-questions/
https://www.biocentury.com/bc-extra/clinical-news/2018-10-12/phase-ii-data-mercks-btk-inhibitor-highlighted-ectrims